



Published in final edited form as:

JHLT Open. 2023 October ; 1: . doi:10.1016/j.jhlto.2023.100007.

Is pulmonary arterial hypertension associated with schistosomiasis distinct from pulmonary arterial hypertension associated with portal hypertension?

Brian B. Graham^{a,b}, Joan F. Hilton^c, Michael H. Lee^{a,b}, Rahul Kumar^{a,b}, Dara Fonseca Balladares^{a,b}, Farbod N. Rahaghi^d, Raúl San José Estépar^e, Claudia Mickael^f, Rodrigo Luís Barbosa Lima^g, Camila M.C. Loureiro^h, Juliana Lucenaⁱ, Rudolf K.F. Oliveiraⁱ, Ricardo de Amorim Corrêa^j

^aLung Biology Center, University of California San Francisco, San Francisco, California

^bPulmonary Division, San Francisco General Hospital, San Francisco, California

^cDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California

^dPulmonary Medicine, Brigham and Women's Hospital, Boston, Massachusetts

^eApplied Chest Imaging Laboratory, Brigham and Women's Hospital, Boston, Massachusetts

^fPulmonary and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado

^gPulmonary Medicine, Hospital Júlia Kubitscheck, Belo Horizonte, Minas Gerais, Brazil

^hPulmonary Medicine, Santa Casa da Bahia, Salvador, Bahia, Brazil

ⁱDivision of Respiratory Diseases, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil

^jInternal Medicine/Pulmonary Division, Medical School, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

Abstract

Pulmonary arterial hypertension associated with schistosomiasis (SchPAH) and pulmonary arterial hypertension associated with portal hypertension (PoPAH) are lung diseases that develop in the presence of liver diseases. However, mechanistic pathways by which the underlying liver conditions and other drivers contribute to the development and progression of pulmonary arterial hypertension (PAH) are unclear for both etiologies. In turn, these unknowns limit certainty of strategies to prevent, diagnose, and reverse the resultant PAH. Here we consider specific mechanisms that contribute to SchPAH and PoPAH, identifying those that may be shared and those that appear to be unique to each etiology, in the hope that this exploration will both highlight known causal drivers and identify knowledge gaps appropriate for future research. Overall, the key

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Reprint requests: Brian B. Graham, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, 1001 Potrero Ave, Bldg 5, Room 5J1, San Francisco, CA 94127. brian.graham@ucsf.edu.

pathophysiologic differences that we identify between SchPAH and PoPAH suggest that they are not variants of a single condition.

Keywords

pulmonary arterial hypertension; schistosomiasis; portal hypertension; TGF-beta signaling; thromboembolism

Background—Why is this important?

Pulmonary arterial hypertension associated with schistosomiasis (SchPAH) and pulmonary arterial hypertension associated with portal hypertension (PoPAH) are both forms of pulmonary arterial hypertension (PAH), classified as group 1 by the 2022 European Society of Cardiology and European Respiratory Society Guidelines.¹ In Western countries, PAH is rare, found in 15 to 50 persons per million within the United States (US) and Europe.¹ In the US-based PVDomics cross-sectional survey,² PoPAH and SchPAH accounted for 5% and < 3% of 353 PAH cases, whereas idiopathic PAH accounted for 45%. However, in tropical countries where schistosomiasis is endemic, SchPAH is likely to be more prevalent than in the US and Europe.

Schistosomiasis results from infection by the trematode flatworm *Schistosoma*, a snail-borne parasite endemic in tropical regions of Africa, Brazil, the Middle East, and Southeast Asia. Over 250 million people worldwide have schistosomiasis.³ It is estimated that 0.25% to 1% of individuals with chronic schistosomiasis develop SchPAH.⁴ The regions where the parasitic infection is prevalent are often resource challenged, severely limiting effective diagnosis and treatment of PAH. After entry into the body, the worms migrate to the target organ (generally the portal vein) where they persist for years. A majority of the eggs erode through the intestinal wall to return to the environment and complete the lifecycle, but a minority of the ~100 µm diameter eggs are retained in the host, floating downstream to the liver, and causing granulomatous type 2 inflammation. About 10% of chronically infected individuals develop dense periportal fibrosis, termed schistosomiasis-associated hepatosplenic disease (SchHSD).⁵ SchHSD causes portal hypertension, portocaval shunting, and the transit of *Schistosoma* eggs to systemic veins, and then the lungs (Figure 1). The pulmonary pathology of SchPAH includes type 2 inflammation around the eggs,⁶ but otherwise, the pathology is similar to other PAH etiologies, including plexiform lesions.

PoPAH most commonly occurs in the setting of liver cirrhosis caused by alcohol, viral hepatitis, autoimmune hepatitis, and primary biliary cirrhosis. PoPAH can also occur in noncirrhotic portal hypertensive liver diseases, including nonalcoholic steatohepatitis,⁷ and primary sclerosing cholangitis^{7,8} which has more limited hepatocellular injury. In cirrhosis, decreased liver function reduces clearance of vasoactive substances including atrial natriuretic peptide, renin, angiotensin II, and aldosterone.⁹ This results in systemic vasodilation and increased cardiac output, which has been hypothesized to increase pulmonary vascular shear stress, resulting in endothelial cell injury and vascular remodeling.^{10,11} It is estimated 2% to 10% of those with portal hypertension develop

PoPAH.¹² Polymorphisms in estrogen metabolism genes and greater plasma levels of estrogen pathway metabolites correlate with the development of PoPAH in those at risk.^{8,13}

A major knowledge gap in the PAH field is whether the liver disease present in both SchPAH and PoPAH, hepatosplenic schistosomiasis and most commonly cirrhosis, respectively, contributes to these pulmonary vascular diseases in the same manner. Patients with both SchPAH and PoPAH benefit from treatment with PAH-targeted therapies,^{14,15} but while these medications reduce symptoms and likely improve survival,^{16–18} they likely do not directly reverse the mechanisms that underlie the diseases, which are not well understood. Therefore, clarifying shared mechanisms will enhance understanding of the pathogenesis and effective clinical management of both etiologies.

SchPAH and PoPAH commonalities

Hepatocellular injury

SchHSD is generally not thought to have the same severity of liver dysfunction as cirrhosis, as less of the total parenchyma is fibrotic. Biochemical studies indicate the synthetic dysfunction is more severe among those with PoPAH than those with SchHSD.^{7,19,20} However, hepatocellular injury severity is not associated with the development of PoPAH (Table 1) and, more specifically, the Model for End-Stage Liver Disease score does not correlate with the incidence of PoPAH.^{7,21} Furthermore, PoPAH can complicate liver diseases that have relatively little hepatocellular dysfunction. In SchPAH, there are case reports of *S. haematobium* infection causing PAH²²: *S. haematobium* worms home to the bladder wall, causing urinary disease without liver disease. Lastly, mice experimentally challenged with intraperitoneal *Schistosoma* egg sensitization followed by intravenous egg administration and embolism of the pulmonary arteries (PAs) develop pulmonary hypertension (PH), a model which has no liver disease at all.^{23,24} Overall, it is apparent that hepatocellular injury is shared by both SchPAH and PoPAH, but is actually unlikely to directly contribute to the development of either form of PAH.

Portal hypertension and portosystemic shunts

The severity of portal hypertension is likely comparable between SchPAH and PoPAH, as the incidence of variceal bleeding is similar,^{25–27} despite the fibrosis distribution being periportal in SchHSD vs bridging in liver cirrhosis. Entirely aside from parenchymal forms of liver disease, portosystemic shunts resulting from congenital malformations are associated with PAH. Congenital extrahepatic portocaval shunt (CEPS) is caused by abnormal embryonic development of the portal vein, and many case series and case reports have described PAH occurring in the setting of CEPS.^{28–30} In summary, both portal hypertension and portosystemic shunts are shared between SchPAH and PoPAH, and are likely to contribute to the pathogenesis of both etiologies.

Dysregulated transforming growth factor beta (TGF- β) signaling

Alterations in transforming growth factor beta (TGF- β) superfamily signaling underlies many PAH etiologies. Familial PAH most commonly results from bone morphogenetic protein (BMP) receptor type II loss of function, causing decreased BMP pathway signaling

and a reciprocal increase in TGF- β pathway signaling. Patients with PoPAH have evidence of reduced BMP signaling, including less serum BMP9³¹ and increased endoglin³² (which functions as a BMP ligand trap,³³ thereby decreasing BMP signaling). In comparison, SchPAH has increased TGF- β pathway signaling (which would reciprocally decrease BMP signaling), with higher serum TGF- β ³⁴ and increased tissue phospho-Smad2/3 expression.²⁴ In *Schistosoma*-exposed mice, blocking TGF- β signaling prevents PH.^{23,24} Overall, it is likely that a shift in TGF- β family signaling, with increased TGF- β pathway and less BMP pathway signaling, is a commonality in both SchPAH and PoPAH, and is likely to contribute to the pathogenesis of both.

Thromboembolism

Thromboembolism likely contributes to all forms of PAH in varying degrees, related to a hypercoagulable state and slower blood flow through lung regions.³⁵ In PoPAH, thrombi formed in the portal veins may travel through portocaval shunts to become pulmonary emboli, with relatively frequent pulmonary emboli described in this condition.^{36,37} Thromboembolic disease has also been reported in SchPAH.³⁸ Patients with SchPAH can have aneurysmal proximate PAs, with mural thrombus, but it is not clear if there is also distal embolization in these cases. In summary, thromboembolism may be relatively common in and contribute to the development of both SchPAH and PoPAH, but here the evidence is not very clear, and there may be cases that develop in the absence of thromboemboli.

SchPAH and PoPAH distinctions

PoPAH: Higher cardiac output and endothelial shear stress

Increased cardiac output is observed in PoPAH,⁷ leading to shear stress on the pulmonary endothelium which may contribute to PoPAH pathogenesis.^{10,11} In contrast, patients with SchPAH have normal or low cardiac output,^{39,40} as seen in other (non-PoPAH) forms of PAH.

SchPAH: Greater pulmonary inflammation

Perivascular inflammation is uncommon in PoPAH, although histologic series are limited.³⁶ In contrast, perivascular inflammation is prominent, robust, and widely described in SchPAH, including T cells, mast cells, and dendritic cells,⁴¹ and markers of type 2 inflammation.⁶ Blocking type 2 inflammation and depleting T cells are protective in *Schistosoma*-PH mice.^{6,42} Inflammation of the pulmonary vasculature in SchPAH may contribute to proximal PA aneurysms,⁴³ as is seen in other inflammatory conditions including Behçet disease and Hughes-Stovin syndrome.^{44,45}

Disease trajectories

Patients with PoPAH who have not undergone transplantation have a prognosis worse than prototypical idiopathic PAH,⁴⁶ whereas patients with SchPAH are thought to have a prognosis better than idiopathic PAH.¹⁵

Remarkably, the relative trajectories reverse when the underlying liver condition is treated. Patients with PoPAH who undergo liver transplantation almost universally have some degree of improvement.^{47,48} These data suggest that in PoPAH, the driving agent is fundamentally the liver, as replacing the liver results in pulmonary vascular recovery. A potential mechanistic explanation is when the cardiac output normalizes, the endothelial shear stress also normalizes, and the pulmonary vasculature can heal. Reversing pulmonary vascular pathology by unloading is also described in humans with PAH associated with congenital heart disease,⁵⁰ and in animal models.⁴⁹

In patients with SchHSD, antihelminthic treatment with praziquantel results in less liver fibrosis⁵¹ and reduced portal hypertension.⁵² However, patients with SchPH treated with praziquantel do not appear to have improvement in their lung disease.^{53,54} Parasite eradication may slow the rate of progression by stopping further egg deposition in the lungs, but patients still die of SchPAH despite receiving praziquantel, avoiding reinfection by moving away from endemic settings, and not having any eggs in their lungs at the time of death.³⁸ These data suggest that in SchPAH, after a certain point, the liver pathology and the lung pathology become disconnected: the liver improves but the lung does not. Potentially the lung inflammation initially triggered by *Schistosoma* eggs results in persistent pulmonary vascular pathology, now independent of either the parasite or the liver disease. However, these observations may be confounded by less access to care including liver transplantation, more advanced disease, and the potential for chronic reinfection in endemic settings.

Summary and future directions

Overall, we suggest that PoPAH and SchPAH are unlikely to arise from the same pathologic mechanisms, and SchPAH should not be considered a variant of PoPAH. It is likely that both portosystemic shunts and abnormal TGF- β signaling contribute to the pathology of both PoPAH and SchPAH, whereas the hepatocellular injury present in both is unlikely to contribute to either. Increased vascular shear stress from increased cardiac output probably uniquely contributes to PoPAH and reverses at least in part by liver transplantation. In contrast, the localized type 2 inflammation arising from egg embolization is a unique contributor to SchPAH.

There remain open questions about the overlap between the 2 conditions (Table 2). We suggest that identifying molecular pathways that are shared by the 2 etiologies increases the probability that these are underlying disease drivers, and if targeted would be more likely to have clinical benefit.

It would be useful to assess the same plasma and lung tissue biomarkers in both conditions to identify potentially shared cellular pathways. It would also be helpful to have better tools to quantify the degree of exposure over time, such as the burdens of parasitic and/or viral infection in SchPAH and cirrhosis in PoPAH, respectively. Genetic variants and environmental exposure factors likely contribute to the development of both SchPAH and PoPAH in at-risk individuals. An important environmental exposure is the potential for

coinfection, such as with HIV which can independently cause PAH, as the combination is likely to result in synergistic PAH pathobiology.⁵⁵

Imaging studies would help characterize SchPAH and PoPAH pathology noninvasively, including computed tomography imaging to assess the pulmonary vasculature, and ventilation perfusion study (V/Q) imaging to identify thromboembolic disease. In experimental animal models of each condition, interrogating whether targeting the same pathways can suppress PH will identify candidate shared pathophysiologic mechanisms. Ultimately, clinical trials targeting pathogenic mechanisms need to be performed. As TGF- β family signaling likely underlies both conditions, we hypothesize the activin/growth differentiation factor ligand trap sotatercept will work in both PoPAH and SchPAH, as it has shown great promise in clinical trials,^{56,57} but has not yet been studied in either etiology.

Disclosure statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Brian Graham reports financial support was provided by National Institutes of Health. Claudia Mickael reports financial support was provided by National Institutes of Health. Camila Melo Coelho Loureiro reports financial support was provided by Janssen-Cilag Pharmaceutical. Camila Melo Coelho Loureiro reports financial support was provided by Bayer SA. Dara Fonseca Balladares reports financial support was provided by National Institutes of Health. Farbod N Rahaghi reports financial support was provided by National Institutes of Health. Joan F. Hilton reports financial support was provided by National Institutes of Health. Michael Lee reports financial support was provided by National Institutes of Health. Michael Lee reports financial support was provided by Fulbright US Scholar Program. Michael Lee reports financial support was provided by US Department of Defense. Rahul Kumar reports financial support was provided by American Heart Association Inc. Rahul Kumar reports financial support was provided by American Thoracic Society. Rahul Kumar reports financial support was provided by The Cardiovascular Medical Research and Education Fund. Rahul Kumar reports financial support was provided by United Therapeutics Corporation. Ricardo Correa reports financial support was provided by Janssen-Cilag Farmacêutica. Ricardo Correa reports financial support was provided by Bayer SA. Raul San Jose Estepar reports financial support was provided by National Institutes of Health. Raul San Jose Estepar reports financial support was provided by Lung Biotechnology PBC. Raul San Jose Estepar reports financial support was provided by Insmmed Inc. Raul San Jose Estepar reports financial support was provided by Boehringer Ingelheim GmbH. Raul San Jose Estepar reports financial support was provided by IMBiotechnologies Ltd. Raul San Jose Estepar reports financial support was provided by Leuko Labs. Raul San Jose Estepar reports financial support was provided by Chiesi Pharmaceuticals GMBH. Rudolf Oliveira reports financial support was provided by National Council for Scientific and Technological Development (CNPq, Brazil). Rodrigo Lima reports financial support was provided by GSK Brazil.

Acknowledgments

Grant funding was provided by R01HL135872 and P01HL152961 to B.B.G.; W81XWH2210457 from the US Department of Defense, Fulbright Scholarship (12398-BR), and K08HL168310 to M.H.L.; American Heart Association Grant 19CDA34730030, ATS Foundation/Pulmonary Hypertension Association Research Fellowship, the Cardiovascular Medical Research Fund and United Therapeutics Jenesis Innovative Research Award to R.K.; R01HL135872-06S1 to D.F.B.; and 1K01HL161024-01 to C.M.; and Grant for Research Productivity from the National Council for Scientific and Technological Development (CNPq, Brazil, grant 313284/2021-0) to R.K.F.O.

References

- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 2023;61:2200879. [PubMed: 36028254]
- Hemnes AR, Leopold JA, Radeva MK, et al. Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease. *J Am Coll Cardiol* 2022;80:697–718. [PubMed: 35953136]
- Lo NC, Bezerra FSM, Colley DG, et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. *Lancet Infect Dis* 2022;22:e327–35. [PubMed: 35594896]
- Sibomana JP, Campeche A, Carvalho-Filho RJ, et al. Schistosomiasis pulmonary arterial hypertension. *Front Immunol* 2020;11:608883. [PubMed: 33362796]
- Fataar S, Bassiony H, Satyanath S, Vassileva J, Hanna RM. Characteristic sonographic features of schistosomal periportal fibrosis. *AJR Am J Roentgenol* 1984;143:69–71. [PubMed: 6610333]
- Kumar R, Mickael C, Chabon J, et al. The causal role of IL-4 and IL-13 in schistosoma mansoni pulmonary hypertension. *Am J Respir Crit Care Med* 2015;192:998–1008. [PubMed: 26192556]
- Krowka MJ, Swanson KL, Frantz RP, McGoan MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. *Hepatology* 2006;44:1502–10. [PubMed: 17133488]
- Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. *Am J Respir Crit Care Med* 2009;179:835–42. [PubMed: 19218192]
- Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. *Liver Int* 2018;38:570–80. [PubMed: 28921803]
- Salibe-Filho W, Araujo TLS, G Melo E, et al. Shear stress-exposed pulmonary artery endothelial cells fail to upregulate HSP70 in chronic thromboembolic pulmonary hypertension. *PloS One* 2020;15:e0242960. [PubMed: 33270690]
- Schäfer M, Kheifets VO, Schroeder JD, et al. Main pulmonary arterial wall shear stress correlates with invasive hemodynamics and stiffness in pulmonary hypertension. *Pulm Circ* 2016;6:37–45. [PubMed: 27076906]
- Thomas C, Glinkskii V, de Jesus Perez V, Sahay S. Portopulmonary hypertension: from bench to bedside. *Front Med* 2020;7:569413.
- Al-Naamani N, Krowka MJ, Forde KA, et al. Estrogen signaling and portopulmonary hypertension: the pulmonary vascular complications of liver disease study (PVCLD2). *Hepatology* 2021;73:726–37.
- Jose A, Kay D, Elwing JM. Treatment of portopulmonary hypertension (PoPH): a review. *J Liver Transplant* 2022;6:100071.
- Knafl D, Gerges C, King CH, Humbert M, Bustinduy AL. Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. *Eur Respir Rev* 2020;29:190089. [PubMed: 32024722]
- Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. *Am J Transplant* 2008;8:2445–53. [PubMed: 18782292]
- Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. *Liver Transpl* 2007;13:875–85. [PubMed: 17539008]
- Savale L, Guimas M, Ebstein N, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. *J Hepatology* 2020;73:130–9. [PubMed: 32145258]

19. Leite LAC, Pimenta Filho AA, Martins da Fonseca CS, et al. Hemostatic dysfunction is increased in patients with hepatosplenic schistosomiasis mansoni and advanced periportal fibrosis. *PLoS Negl Trop Dis* 2013;7:e2314. [PubMed: 23875049]
20. Atsukawa M, Tsubota A, Kondo C, et al. Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study. *Hepatol Int* 2023;17:139–49. [PubMed: 36477691]
21. Shao Y, Yin X, Qin T, Zhang R, Zhang Y, Wen X. Prevalence and associated factors of portopulmonary hypertension in patients with portal hypertension: a case-control study. *BioMed Res Int* 2021;2021:5595614. [PubMed: 33987440]
22. Damluji SF, Al-Khoury M, Johnstone RM. COR pulmonale due to chronic infestation with schistosoma haematobium. *J Trop Med Hyg* 1964;67:220–3. [PubMed: 14203910]
23. Kumar R, Mickael C, Kassa B, et al. TGF- β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension. *Nat Commun* 2017;8:15494. [PubMed: 28555642]
24. Graham BB, Chabon J, Gebreab L, et al. Transforming growth factor- β signaling promotes pulmonary hypertension caused by *Schistosoma mansoni*. *Circulation* 2013;128:1354–64. [PubMed: 23958565]
25. Gunda DW, Kilonzo SB, Manyiri PM, Peck RN, Mazigo HD. Morbidity and mortality due to *Schistosoma mansoni* related periportal fibrosis: could early diagnosis of varices improve the outcome following available treatment modalities in sub Saharan Africa? A scoping review. *Trop Med Infect Dis* 2020;5:20. [PubMed: 32028581]
26. Sarangapani A, Shanmugam C, Kalyanasundaram M, Rangachari B, Thangavelu P, Subbarayan JK. Noninvasive prediction of large esophageal varices in chronic liver disease patients. *Saudi J Gastroenterol* 2010;16:38–42. [PubMed: 20065573]
27. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology* 2007;46:922–38. [PubMed: 17879356]
28. Lin KY, Chen H, Yu L. Pulmonary arterial hypertension caused by congenital extrahepatic portocaval shunt: a case report. *BMC Cardiovasc Disord* 2019;19:141. [PubMed: 31196005]
29. Law YM, Mack CL, Sokol RJ, Rice M, Parsley L, Ivy D. Cardiopulmonary manifestations of portovenous shunts from congenital absence of the portal vein: pulmonary hypertension and pulmonary vascular dilatation. *Pediatr Transplant* 2011;15:E162–8. [PubMed: 20565694]
30. Hlavata T, Kaldararova M, Klauco F, Drangova E, Reptova A, Simkova I. Congenital absence of the portal vein as a rare cause of portopulmonary hypertension—a case study series. *Med Kaunas Lith* 2022;58:1484.
31. Nikolic I, Yung LM, Yang P, et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension. *Am J Respir Crit Care Med* 2019;199:891–902. [PubMed: 30312106]
32. Malhotra R, Paskin-Flerlage S, Zamanian RT, et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. *Pulm Circ* 2013;3:369–80. [PubMed: 24015338]
33. Lawera A, Tong Z, Thorikay M, et al. Role of soluble endoglin in BMP9 signaling. *Proc Natl Acad Sci U S A* 2019;116:17800–8. [PubMed: 31431534]
34. Ferreira RDCDS, Montenegro SML, Domingues ALC, et al. TGF beta and IL13 in *Schistosomiasis mansoni* associated pulmonary arterial hypertension; a descriptive study with comparative groups. *BMC Infect Dis* 2014;14:282. [PubMed: 24886277]
35. Bazan IS, Fares WH. Hypercoagulability in pulmonary hypertension. *Clin Chest Med* 2018;39:595–603. [PubMed: 30122183]
36. Matsubara O, Nakamura T, Uehara T, Kasuga T. Histometrical investigation of the pulmonary artery in severe hepatic disease. *J Pathol* 1984;143:31–7. [PubMed: 6737114]
37. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. *J Am Coll Cardiol* 1987;10:1233–8. [PubMed: 3680790]
38. Graham BB, Chabon J, Bandeira A, Espinheira L, Butrous G, Tuder RM. Significant intrapulmonary *Schistosoma* egg antigens are not present in schistosomiasis-associated pulmonary hypertension. *Pulm Circ* 2011;1:456–61. [PubMed: 22530100]

39. Piscoya Roncal CG, Mendes AA, Muniz MTC, et al. Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil. *Int J Cardiol Heart Vasc* 2019;25:100373. [PubMed: 31720370]
40. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. *Circulation* 2009;119:1518–23. [PubMed: 19273723]
41. Mauad T, Pozzan G, Lanças T, et al. Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension. *J Infect* 2014;68:90–8. [PubMed: 23954614]
42. Kumar R, Mickael C, Kassa B, et al. Th2 CD4+ T cells are necessary and sufficient for schistosoma-pulmonary hypertension. *J Am Heart Assoc* 2019;8:e013111. [PubMed: 31339057]
43. Hoette S, Figueiredo C, Dias B, et al. Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. *BMC Pulm Med* 2015;15:118. [PubMed: 26459359]
44. Khalid U, Saleem T. Hughes-Stovin syndrome. *Orphanet J Rare Dis* 2011;6:15. [PubMed: 21489283]
45. Seyahi E, Yazici H. Behçet's syndrome: pulmonary vascular disease. *Curr Opin Rheumatol* 2015;27:18–23. [PubMed: 25415527]
46. Lazaro Salvador M, Quezada Loaiza CA, Rodríguez Padial L, et al. Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry. *Intern Med J* 2021;51:355–65. [PubMed: 31943676]
47. Savale L, Sattler C, Coilly A, et al. Long-term outcome in liver transplantation candidates with portopulmonary hypertension. *Hepatology* 2017;65:1683–92. [PubMed: 27997987]
48. Reymond M, Barbier L, Salame E, et al. Does portopulmonary hypertension impede liver transplantation in cirrhotic patients? A French multicentric retrospective study. *Transplantation* 2018;102:616–22. [PubMed: 29077657]
49. Abe K, Shinoda M, Tanaka M, et al. Haemodynamic unloading reverses occlusive vascular lesions in severe pulmonary hypertension. *Cardiovasc Res* 2016;111:16–25. [PubMed: 27037259]
50. Masaki N, Saiki Y, Endo M, et al. Evidence of pulmonary vascular reverse remodeling after pulmonary artery banding performed in early infancy in patients with congenital heart defects. *Circ J* 2018;82:684–90. [PubMed: 29249737]
51. Bina JC. Effect of specific therapy on the prevention and reversal of severe forms of schistosomiasis. *Mem Inst Oswaldo Cruz* 1987;82(Suppl 4):331–2. [PubMed: 3151107]
52. Richter J. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. *Acta Trop* 2000;77:111–31. [PubMed: 10996127]
53. Fernandes CJCS, Dias BA, Jardim CVP, et al. The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. *Chest* 2012;141:923–8. [PubMed: 22030800]
54. Emanuel A, Prata A, Bina JC, Guimarães A. Persistent schistosomal pulmonary hypertension in a patient after reversion of a hepato-splenic form: presentation of a case. *Rev Soc Bras Med Trop* 1986;19:171–2. [PubMed: 3685530]
55. Medrano-Garcia S, Morales-Cano D, Barreira B, et al. HIV and Schistosoma co-exposure leads to exacerbated pulmonary endothelial remodeling and dysfunction associated with altered cytokine landscape. *Cells* 2022;11:2414. [PubMed: 35954255]
56. Hoepfer MM, Badesch DB, Ghofrani HA, et al. STELLAR trial investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. *N Engl J Med* 2023;388:1478–90. [PubMed: 36877098]
57. Humbert M, McLaughlin V, Gibbs JSR, et al. PULSAR trial investigators. Sotatercept for the treatment of pulmonary arterial hypertension. *N Engl J Med* 2021;384:1204–15. [PubMed: 33789009]




Figure 1. Proposed pathways of mechanisms underlying SchPAH (yellow), PoPAH (blue), or shared by both (green). PoPAH, pulmonary arterial hypertension associated with portal hypertension; SchPAH, pulmonary arterial hypertension associated with schistosomiasis.

Table 1
 Summary of Pathophysiologic Mechanisms That are Likely to be Shared by SchPAH and PoPAH, or Unique to SchPAH or to PoPAH

Potential mechanisms	Relevant in SchPAH?	Relevant in PoPAH?
Liver-specific		
Hepatocellular injury	Unlikely	Unlikely
Portal hypertension	Likely	Likely
Portocaval shunting	Likely	Likely
Lung-specific		
↓ BMP / ↑ TGF-β signaling	Likely	Likely
Egg embolization	Likely	No
Type 2 inflammation	Likely	Unlikely
Circulating factors		
Altered vasoactive metabolite concentrations	Unknown	Likely
↑ Estrogen	Unknown	Likely
↓ BMP9	Unknown	Likely
↑ TGF-β	Likely	Unknown
Thromboembolism	Possibly	Possibly
Cardiac and shear stress	Unlikely	Likely
Pulmonary vessel shear stress	Unlikely	Likely

BMP, bone morphogenetic protein; TGF-β, transforming growth factor beta.

Proposed Questions for Future Research Comparing SchPAH and PoPAH, and Potential Approaches That May Be Considered

Table 2

Questions for future research	Potential approaches
<p>Are circulating biomarkers shared or different?</p> <ul style="list-style-type: none"> - Estrogen metabolism - TGF-β family signaling - Type 2 inflammation - Markers of liver injury 	<p>Assess candidates in plasma samples from patients with SchPAH and PoPAH</p> <ul style="list-style-type: none"> - Estrogen - BMP9, soluble endoglin, TGF-β - IL-4, IL-13 - Vasoactive substances - Higher throughput 'omics approaches <p>Analyze autopsy or explanted lung tissue</p> <ul style="list-style-type: none"> - Cytokines: IL-4, IL-13, TGF-β family - Cells: eosinophils, macrophages, and cell phenotypes
<p>Is there evidence of similar inflammation in PoPAH and SchPAH lung tissue?</p>	<p>Interrogate animal models</p> <ul style="list-style-type: none"> - Test if increasing BMP9 inhibits experimental SchPAH - Test if inhibiting TGF-β or IL-4/IL-13 prevents experimental PoPAH <p>Compare pulmonary vasculature by etiology</p> <ul style="list-style-type: none"> - Morphology based on CT imaging - Morphometric and stereologic assessments of lung tissue
<p>Does blocking the same pathways inhibit animals models of the diseases?</p> <p>- Does increasing BMP signaling protect in SchPAH?</p> <p>- Does blocking TGF-β or type 2 inflammation protect in PoPAH?</p>	<p>Compare pulmonary vasculature by etiology</p> <ul style="list-style-type: none"> - Morphology based on CT imaging - Morphometric and stereologic assessments of lung tissue <p>Assessment of portal pressure</p> <ul style="list-style-type: none"> - Directly by hemodynamics - Indirectly such as by assessing portal vein diameter or spleen volume on CT imaging - Assessing patients with SchPAH and PoPAH, as compared to at-risk but PAH negative patients (SchHSD and cirrhosis, respectively)
<p>Do patients with SchPAH and PoPAH have similar vascular morphology?</p>	<p>Systematic comparisons using CT and V/Q imaging</p> <ul style="list-style-type: none"> - Human epidemiologic studies to detect risk factors - Animal models with coexposure approaches
<p>Do patients with SchPAH and PoPAH have comparable portal hypertension severity?</p> <p>Does portal hypertension severity correlate with PAH development?</p>	<p>Targeted genetic studies in both cohorts (particularly in SchPAH, where this has not been done yet)</p>
<p>Is thromboembolic disease a contributor to both SchPAH and PoPAH?</p> <p>What are environmental risk factors for the development of SchPAH and PoPAH?</p> <ul style="list-style-type: none"> - Coinfections, such as HIV - Pollution or toxins including alcohol 	<p>Targeted genetic studies in both cohorts (particularly in SchPAH, where this has not been done yet)</p>
<p>Are there shared genetic risk factors for the development of SchPAH and PoPAH?</p>	<p>BMP, bone morphogenetic protein; CT, computed tomography; PAH, pulmonary arterial hypertension associated with portal hypertension; SchHSD, schistosomiasis-associated hepatosplenic disease; SchPAH, pulmonary arterial hypertension associated with schistosomiasis; TGF, transforming growth factor; V/Q, ventilation perfusion study.</p>